GlassScriptPhysician profile
Jennifer E Halfmann
NPI 1609146448
$1,283.06
in general payments reported to CMS, 2019-2025
14 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $294 · 2023: $421 · 2024: $256 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $379.30 | 2021-2025 | Leqvio |
| Medtronic, INC. | $202.34 | 2022-2024 | Onyx Frontier, Telescope, Corevalve Evolut R |
| Merck Sharp & Dohme LLC | $159.96 | 2021-2025 | Verquvo |
| Abbott Laboratories | $102.10 | 2022 | |
| Pfizer INC. | $91.46 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $88.28 | 2022-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $79.02 | 2024-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $55.18 | 2021-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.18 | 2021-2023 | Jardiance |
| Abbvie INC. | $22.31 | 2021 | |
| Boston Scientific Corporation | $19.96 | 2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.80 | 2024-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $16.08 | 2021 | |
| Amgen INC. | $14.09 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Halfmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.